$ANEB Potential Breakout I'm not sure if I'm charting this correctly but I think this stock broke above the trend line into the upside in the post market hours.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.31 USD
−8.20 M USD
0.00 USD
9.28 M
About Anebulo Pharmaceuticals, Inc.
Sector
CEO
Richard Anthony Cunningham
Headquarters
Lakeway
Website
Founded
2020
FIGI
BBG00ZWY5GC8
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ANEB is 1.62 USD — it has increased by 26.26% in the past 24 hours. Watch Anebulo Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Anebulo Pharmaceuticals, Inc. stocks are traded under the ticker ANEB.
ANEB stock has fallen by −10.71% compared to the previous week, the month change is a −15.54% fall, over the last year Anebulo Pharmaceuticals, Inc. has showed a −36.22% decrease.
We've gathered analysts' opinions on Anebulo Pharmaceuticals, Inc. future price: according to them, ANEB price has a max estimate of 8.00 USD and a min estimate of 8.00 USD. Watch ANEB chart and read a more detailed Anebulo Pharmaceuticals, Inc. stock forecast: see what analysts think of Anebulo Pharmaceuticals, Inc. and suggest that you do with its stocks.
ANEB reached its all-time high on May 21, 2021 with the price of 9.33 USD, and its all-time low was 0.80 USD and was reached on Dec 20, 2024. View more price dynamics on ANEB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ANEB stock is 53.64% volatile and has beta coefficient of 1.26. Track Anebulo Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Anebulo Pharmaceuticals, Inc. there?
Today Anebulo Pharmaceuticals, Inc. has the market capitalization of 32.42 M, it has decreased by −5.07% over the last week.
Yes, you can track Anebulo Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Anebulo Pharmaceuticals, Inc. is going to release the next earnings report on Feb 7, 2025. Keep track of upcoming events with our Earnings Calendar.
ANEB earnings for the last quarter are −0.08 USD per share, whereas the estimation was −0.05 USD resulting in a −60.00% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about Anebulo Pharmaceuticals, Inc. earnings.
Anebulo Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ANEB net income for the last quarter is −2.20 M USD, while the quarter before that showed −1.35 M USD of net income which accounts for −63.02% change. Track more Anebulo Pharmaceuticals, Inc. financial stats to get the full picture.
No, ANEB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 3.00 employees. See our rating of the largest employees — is Anebulo Pharmaceuticals, Inc. on this list?
Like other stocks, ANEB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Anebulo Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Anebulo Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Anebulo Pharmaceuticals, Inc. stock shows the sell signal. See more of Anebulo Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.